iShares Biotechnology ETF
840 hedge funds and large institutions have $5.12B invested in iShares Biotechnology ETF in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 202 increasing their positions, 311 reducing their positions, and 65 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
21% less funds holding in top 10
Funds holding in top 10: 14 → 11 (-3)
23% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 65
35% less repeat investments, than reductions
Existing positions increased: 202 | Existing positions reduced: 311
Holders
840
Holding in Top 10
11
Calls
$233M
Puts
$234M
Top Buyers
| 1 | +$47.9M | |
| 2 | +$46M | |
| 3 | +$32M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$23.6M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$17.4M |
Top Sellers
| 1 | -$93.5M | |
| 2 | -$68.1M | |
| 3 | -$36.4M | |
| 4 |
HMH
Hackensack Meridian Health
Edison,
New Jersey
|
-$29.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$18.8M |